Federated Hermes, Inc. Iveric Bio, Inc. Transaction History

Federated Hermes, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$18.67 - $24.56 $8.77 Million - $11.5 Million	470,000 New	470,000 $11.4 Million
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $17,218 - $35,683	-1,888 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$12.15 - $16.83 $3,122 - $4,325	-257 Reduced 11.98%	1,888 $32,000
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $29,347 - $39,851	-2,122 Reduced 49.73%	2,145 $36,000
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $30,167 - $74,672	4,267 New	4,267 $70,000
Q2 2021 Aug 16, 2021	SELL	$5.69 - $7.17 $39,949 - $50,340	-7,021 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$5.08 - $6.89 $12,374 - $16,784	2,436 Added 53.13%	7,021 $43,000
Q4 2020 Feb 12, 2021	BUY	$5.65 - $7.66 $2,067 - $2,803	366 Added 8.68%	4,585 $32,000
Q3 2020 Nov 12, 2020	BUY	$4.01 - $6.29 $15,823 - $24,820	3,946 Added 1445.42%	4,219 $24,000
Q2 2020 Aug 13, 2020	BUY	$3.06 - $6.6 $312 - $673	102 Added 59.65%	273 $1,000
Q1 2020 May 13, 2020	SELL	$2.83 - $8.44 $141 - $422	-50 Reduced 22.62%	171 $1,000
Q4 2019 Feb 14, 2020	BUY	$0.93 - $8.58 $31 - $291	34 Added 18.18%	221 $2,000
Q3 2019 Nov 14, 2019	SELL	$1.09 - $1.29 $486 - $575	-446 Reduced 70.46%	187 $1,000
Q2 2019 Aug 14, 2019	BUY	$1.21 - $1.48 $765 - $936	633 New	633 $1,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.